Biosimilars have garnered significant press over the past few years, with a primary focus on
savings for employers. This savings is significant, as increased use of biosimilars will allow for
a more competitive drug marketplace. Reduced barriers to biosimilar adoption could generate
savings of about $25 billion over 10 years, or roughly 0.5% of national spending on prescription
drugs. However, other organizations, such as the Association for Accessible Medicines (AAM), indicate
biosimilars savings could project upwards of $133 billion by 2025, but only if policymakers encourage
greater biosimilar adoption.
To help employers overcome these obstacles, the National Alliance of Healthcare Purchaser
Coalitions (National Alliance) brought together seven regional coalitions and more than 60
employers for a series of roundtables across the country. Participating coalitions include:
> Economic Alliance for Michigan
> Florida Alliance for Healthcare Value
> HealthCare 21 Business Coalition
> Houston Business Coalition on Health
> Memphis Business Group on Health
> Lehigh Valley Business Coalition on Healthcare
> Washington Health Alliance